GBM
MCID: GLB002
MIFTS: 67

Glioblastoma (GBM)

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Glioblastoma

MalaCards integrated aliases for Glioblastoma:

Name: Glioblastoma 11 19 58 75 28 53 5 43 14 71
Glioblastoma Multiforme 11 19 58 75 28 53 5 14 16 71
Gbm 11 58
Grade Iv Adult Astrocytic Tumor 11
Primary Glioblastoma Multiforme 11
Adult Glioblastoma Multiforme 11
Spongioblastoma Multiforme 11
Primary Glioblastoma 71
Adult Glioblastoma 71

Characteristics:


Inheritance:

Multigenic/multifactorial 58

Prevelance:

1-9/100000 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:3068
MeSH 43 D005909
SNOMED-CT 68 63634009
MESH via Orphanet 44 D005909
ICD10 via Orphanet 32 C71.9
UMLS via Orphanet 72 C0017636 C1621958
Orphanet 58 ORPHA360
UMLS 71 C0017636 C0278878 C1514422 more

Summaries for Glioblastoma

GARD: 19 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1, Turcot syndrome and Li Fraumeni syndrome.

MalaCards based summary: Glioblastoma, also known as glioblastoma multiforme, is related to brain cancer and glioma, and has symptoms including headache and seizures. An important gene associated with Glioblastoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is miRNAs involved in DNA damage response. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and eye, and related phenotypes are glioblastoma multiforme and abnormal cell morphology

Disease Ontology: 11 A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

Orphanet: 58 Glioblastomas are malignant astrocytic tumors (grade IV according to the WHO classification).

Wikipedia: 75 Glioblastoma, previously known as glioblastoma multiforme (GBM), is one of the most aggressive types of... more...

Related Diseases for Glioblastoma

Diseases related to Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1259)
# Related Disease Score Top Affiliating Genes
1 brain cancer 33.1 MSH2 MIR34A MIR296 MIR222 MIR221 MIR21
2 glioma 32.7 TP73-AS1 MIR34A MIR296 MIR222 MIR221 MIR21
3 high grade glioma 32.6 MIR221 MIR21 MALAT1 HOTAIRM1 HOTAIR GAS5
4 central nervous system cancer 32.1 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
5 neuroblastoma 31.7 MIR34A MIR221 MIR21 MALAT1 HOTAIR GAS5
6 malignant astrocytoma 31.7 MIR34A MIR296 MIR222 MIR221 MIR21 AGAP2-AS1
7 medulloblastoma 31.6 MSH2 MIR34A MIR326 MIR221 MIR182 MIR17HG
8 melanoma 31.5 MIR34A MIR222 MIR221 MIR21 MIR182 MIR137
9 lung cancer 31.5 TP73-AS1 NOS2 MSH2 MIR451A MIR34A MIR296
10 b-cell lymphoma 31.5 MIR17HG MALAT1 HOTAIR GAS5
11 hematologic cancer 31.4 MSH2 MIR34A MIR222 MIR221 MIR21
12 hepatocellular carcinoma 31.3 TP73-AS1 NOS2 MSH2 MIR34A MIR296 MIR222
13 leukemia, acute lymphoblastic 31.3 MSH2 MIR451A MIR222 MIR221 MIR21
14 leukemia, acute myeloid 31.3 MIR451A MIR34A MIR326 MIR296 MIR222 MIR221
15 colorectal cancer 31.2 NOS2 MSH2 MIR451A MIR34A MIR296 MIR222
16 breast cancer 31.2 TP73-AS1 NOS2 MSH2 MIR451A MIR34A MIR222
17 lung cancer susceptibility 3 31.2 MIR296 MIR21 MIR182 MALAT1 HOTAIR GAS5
18 ovarian cancer 31.1 MSH2 MIR34A MIR296 MIR222 MIR221 MIR21
19 central nervous system disease 31.1 MIR34A MIR222 MIR221 MIR21
20 prostate cancer 31.1 MSH2 MIR34A MIR296 MIR222 MIR221 MIR21
21 kidney cancer 31.0 MIR21 MIR182 MALAT1 HOTAIR GAS5
22 renal cell carcinoma, nonpapillary 31.0 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
23 bladder cancer 31.0 MSH2 MIR222 MIR221 MIR21 MALAT1 HOTAIR
24 small cell cancer of the lung 31.0 MIR21 MALAT1 HOTAIR
25 diffuse large b-cell lymphoma 31.0 MIR222 MIR221 MIR21 MIR17HG HOTAIR
26 head and neck cancer 31.0 MIR34A MIR296 MIR222 MIR221 MIR21 GAS5
27 esophageal cancer 31.0 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
28 cellular ependymoma 31.0 MSH2 HOTAIR
29 retinitis pigmentosa 11 31.0 MIR296 MIR182 HOTAIRM1 HOTAIR GAS5
30 pancreatic cancer 30.9 MSH2 MIR34A MIR222 MIR221 MIR21 MALAT1
31 thyroid carcinoma 30.9 MALAT1 HOTAIR GAS5
32 cervical cancer 30.8 MIR34A MIR221 MIR21 MALAT1 HOTAIR GAS5
33 hypertension, essential 30.8 NOS2 MIR34A MIR296 MIR222 MIR221 MIR21
34 myeloma, multiple 30.8 TP73-AS1 MIR221 MIR21 MALAT1 HOTAIR GAS5
35 thyroid cancer, nonmedullary, 1 30.7 MIR222 MIR221 MALAT1 HOTAIR
36 leukemia, chronic lymphocytic 30.7 MIR34A MIR221 MIR21 MIR182 MIR17HG
37 nasopharyngeal carcinoma 30.7 MIR296 MIR21 MALAT1 HOTAIR GAS5
38 spinal disease 30.6 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
39 esophagus squamous cell carcinoma 30.6 TP73-AS1 MIR296 MALAT1 HOTAIR GAS5
40 gastric cancer 30.6 MSH2 MIR451A MIR34A MIR222 MIR221 MIR21
41 rectum cancer 30.6 MSH2 MIR221 MIR21
42 muscular dystrophy, duchenne type 30.6 MIR34A MIR222 MIR221 MIR21
43 nervous system disease 30.5 NOS2 MIR34A MIR296 MIR222 MIR221 MIR21
44 bone disease 30.5 MIR34A MIR222 MIR221 MIR21
45 pancreatic ductal adenocarcinoma 30.5 MIR34A MIR222 MIR221 MIR21 MALAT1 HOTAIRM1
46 thoracic cancer 30.4 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
47 lymphatic system disease 30.4 MIR34A MIR222 MIR221 MIR21 MIR182
48 ovarian epithelial cancer 30.1 MALAT1 HOTAIR
49 mantle cell lymphoma 29.7 MIR17HG MALAT1 GAS5
50 glioma susceptibility 1 11.8

Graphical network of the top 20 diseases related to Glioblastoma:



Diseases related to Glioblastoma

Symptoms & Phenotypes for Glioblastoma

Human phenotypes related to Glioblastoma:

30 58 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 glioblastoma multiforme 30 Obligate (100%) HP:0012174
2 abnormal cell morphology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0025461
3 muscle weakness 58 30 Frequent (33%) Frequent (79-30%)
HP:0001324
4 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
5 headache 58 30 Frequent (33%) Frequent (79-30%)
HP:0002315
6 visual loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0000572
7 abnormal corpus callosum morphology 58 30 Frequent (33%) Frequent (79-30%)
HP:0001273
8 language impairment 58 30 Frequent (33%) Frequent (79-30%)
HP:0002463
9 paralysis 58 30 Frequent (33%) Frequent (79-30%)
HP:0003470
10 cerebral edema 58 30 Frequent (33%) Frequent (79-30%)
HP:0002181
11 emotional lability 30 Frequent (33%) HP:0000712
12 seizure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001250
13 memory impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002354
14 abnormal cerebral white matter morphology 58 Frequent (79-30%)
15 abnormality of nervous system physiology 58 Frequent (79-30%)
16 mood changes 58 Frequent (79-30%)
17 glioblastoma 58 Obligate (100%)

UMLS symptoms related to Glioblastoma:


headache; seizures

Drugs & Therapeutics for Glioblastoma

Drugs for Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 521)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
5
Aminolevulinic acid Approved Phase 3 106-60-5 137
6
Citalopram Approved Phase 2, Phase 3 59729-32-7, 59729-33-8 2771
7
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
8
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
9
Hydroxyurea Approved Phase 3 127-07-1 3657
10
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
11
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
12
Tofacitinib Approved, Investigational Phase 3 477600-75-2 9926791
13
Etoposide Approved Phase 3 33419-42-0 36462
14
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
15
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
16
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
17
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
18
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
19
Duloxetine Approved Phase 3 136434-34-9, 116539-59-4 60835
20
Norepinephrine Approved Phase 3 51-41-2 439260
21
Ascorbic acid Approved, Nutraceutical Phase 3 50-81-7 54676860 54670067 5785
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8 5280382 445354
23
Dexetimide Withdrawn Phase 2, Phase 3 21888-98-2 30843
24
Rindopepimut Investigational Phase 3 1108208-65-6
25
Nimotuzumab Investigational Phase 3 780758-10-3
26
Semustine Experimental, Investigational Phase 3 13909-09-6 5198
27
Veliparib Investigational Phase 2, Phase 3 912444-00-9 11960529
28
Dianhydrogalactitol Investigational Phase 3 23261-20-3
29
Trabedersen Investigational Phase 3 925681-61-4
30 Interferon-alpha Phase 3
31
Imatinib Mesylate Phase 3 220127-57-1
32 GDC-0084 Phase 2, Phase 3
33 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
34
Etoposide phosphate Phase 3 16760419
35 Retinol palmitate Phase 3
36 Protective Agents Phase 3
37 Vitamins Phase 3
38 Mitogens Phase 3
39 Pharmaceutical Solutions Phase 3
40 Dopamine Agents Phase 3
41 Antioxidants Phase 3
42 Analgesics Phase 3
43 Trace Elements Phase 3
44 Micronutrients Phase 3
45 Immunoconjugates Phase 3
46 Antidepressive Agents Phase 3
47 Vasoconstrictor Agents Phase 3
48 Ophthalmic Solutions Phase 3
49 Trans-sodium crocetinate Phase 3
50 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 1528)
# Name Status NCT ID Phase Drugs
1 A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00686725 Phase 4 Temozolomide
2 Pilot Study of Resection and GammaTile Followed by Concomitant External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant in Newly Diagnosed Glioblastoma (GBM) Recruiting NCT05342883 Phase 4
3 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
4 A Single Center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of Neoadjuvant and Adjuvant Pembrolizumab on Top of Standard Chemo-Radiotherapy (Stupp Protocol) in Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme (GBM). Not yet recruiting NCT05235737 Phase 4 Pembrolizumab
5 A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient Terminated NCT01756729 Phase 4
6 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Unknown status NCT03633552 Phase 3 Temozolomide
7 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
8 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
9 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
10 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
11 Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional Unknown status NCT01811121 Phase 3 5-aminolévulinique acid (5-ALA);Placebo
12 Proteome-based Personalized Immunotherapy of Malignant Brain Tumors Unknown status NCT01759810 Phase 2, Phase 3
13 Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV Completed NCT00753246 Phase 3 nimotuzumab
14 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
15 A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme Completed NCT00088400 Phase 3 TransMID
16 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
17 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
18 A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
19 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
20 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
21 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
22 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
23 A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT01450449 Phase 3
24 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
25 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
26 A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM Completed NCT00379470 Phase 3
27 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
28 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
29 Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma Completed NCT01290939 Phase 3 lomustine
30 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
31 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
32 Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
33 A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone Completed NCT00777153 Phase 3 Cediranib;Lomustine Chemotherapy;Placebo Cediranib
34 DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial Completed NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
35 A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498) Completed NCT02617589 Phase 3 Nivolumab;Temozolomide
36 Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC) Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
37 A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) Completed NCT02573324 Phase 2, Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
38 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
39 Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
40 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
41 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
42 Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
43 A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
44 Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial Completed NCT01805453 Phase 3 Losartan;Placebo
45 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
46 Interest of Fluorescein in Fluorescence-guided Resection of Gliomas: A Randomized Study Completed NCT03291977 Phase 3 Fluorescéine Sodique Faure
47 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
48 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
49 A Phase III Randomized Trial of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (Avastin) With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed Glioblastoma (GBM) Recruiting NCT05271240 Phase 3 Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation;Temozolomide and Radiation Alone
50 A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II) Recruiting NCT02685605 Phase 3 Temozolomide

Search NIH Clinical Center for Glioblastoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine

Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma

Genetic tests related to Glioblastoma:

# Genetic test Affiliating Genes
1 Glioblastoma 28
2 Glioblastoma Multiforme 28

Anatomical Context for Glioblastoma

Organs/tissues related to Glioblastoma:

MalaCards : Brain, T Cells, Eye, Myeloid, Spinal Cord, Bone Marrow, Endothelial

Publications for Glioblastoma

Articles related to Glioblastoma:

(show top 50) (show all 33975)
# Title Authors PMID Year
1
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. 53 62 46
19773441 2009
2
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. 53 62 46
18577219 2008
3
Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. 53 62 46
17721077 2007
4
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
5
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. 62 46
20227367 2010
6
MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. 62 46
19559015 2009
7
miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. 62 46
19159078 2009
8
Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). 62 46
18759060 2009
9
MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. 62 46
19013014 2008
10
MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. 62 46
18765229 2008
11
MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. 62 46
18829576 2008
12
Extensive modulation of a set of microRNAs in primary glioblastoma. 62 46
16039986 2005
13
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. 62 46
16024602 2005
14
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. 53 62
19937796 2010
15
Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. 53 62
20177775 2010
16
miR-182 as a prognostic marker for glioma progression and patient survival. 46
20472885 2010
17
Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. 53 62
20514402 2010
18
Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. 53 62
20303140 2010
19
New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. 53 62
20305620 2010
20
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. 53 62
20428822 2010
21
Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. 53 62
20388502 2010
22
IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. 53 62
20428809 2010
23
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells. 53 62
20467331 2010
24
An unusual loss of EGFR gene copy in glioblastoma multiforme in a child: a case report and analysis of a successfully derived HGG-02 cell line. 53 62
20195615 2010
25
Amplicons on chromosome 12q13-21 in glioblastoma recurrences. 53 62
19839052 2010
26
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. 53 62
19841865 2010
27
Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. 53 62
20302512 2010
28
Differential expression and cellular distribution of gamma-tubulin and betaIII-tubulin in medulloblastomas and human medulloblastoma cell lines. 53 62
20162618 2010
29
Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. 53 62
20309962 2010
30
FasL gene knock-down therapy enhances the antiglioma immune response. 53 62
20406899 2010
31
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. 53 62
20457619 2010
32
Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. 53 62
19856144 2010
33
Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. 53 62
20307616 2010
34
Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. 53 62
19810093 2010
35
Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. 53 62
20199106 2010
36
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. 53 62
20372840 2010
37
Integrin alpha 6 regulates glioblastoma stem cells. 53 62
20452317 2010
38
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. 53 62
20457618 2010
39
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. 53 62
20096265 2010
40
The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. 53 62
19937366 2010
41
Prion protein: From physiology to cancer biology. 53 62
19674833 2010
42
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. 53 62
20127344 2010
43
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. 53 62
20171141 2010
44
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. 53 62
20371721 2010
45
Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells. 53 62
20298756 2010
46
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. 53 62
20436671 2010
47
Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. 53 62
20140015 2010
48
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. 53 62
20308316 2010
49
Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. 53 62
20412570 2010
50
A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. 53 62
20360941 2010

Variations for Glioblastoma

ClinVar genetic disease variations for Glioblastoma:

5 (show top 50) (show all 234)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BCOR NM_001123385.2(BCOR):c.3883_3884del (p.Leu1296fs) MICROSAT Other
284290 rs886042842 GRCh37: X:39922288-39922289
GRCh38: X:40063035-40063036
2 H3-3A NM_002107.7(H3-3A):c.103G>A (p.Gly35Arg) SNV Other
438766 rs1553260624 GRCh37: 1:226252155-226252155
GRCh38: 1:226064454-226064454
3 MED12 NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp) SNV Other
438772 rs1556339256 GRCh37: X:70357729-70357729
GRCh38: X:71137879-71137879
4 MSH2 NM_000251.3(MSH2):c.1958_1965del (p.Asn653fs) DEL Pathogenic
590849 rs1558518449 GRCh37: 2:47702360-47702367
GRCh38: 2:47475221-47475228
5 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys) SNV Likely Pathogenic
73058 rs121913254 GRCh37: 1:115256530-115256530
GRCh38: 1:114713909-114713909
6 TP53 NM_000546.6(TP53):c.641A>T (p.His214Leu) SNV Likely Pathogenic
376616 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
7 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely Pathogenic
376478 rs1057519929 GRCh37: 3:178916854-178916854
GRCh38: 3:179199066-179199066
8 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely Pathogenic
12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
9 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely Pathogenic
13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
10 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely Pathogenic
12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
11 IDH1 NM_005896.4(IDH1):c.395G>A (p.Arg132His) SNV Likely Pathogenic
156444 rs121913500 GRCh37: 2:209113112-209113112
GRCh38: 2:208248388-208248388
12 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely Pathogenic
127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
13 TP53 NM_000546.6(TP53):c.584T>A (p.Ile195Asn) SNV Likely Pathogenic
376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
14 TP53 NM_000546.6(TP53):c.374C>T (p.Thr125Met) SNV Likely Pathogenic
183748 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
15 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely Pathogenic
177791 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
16 TP53 NM_000546.6(TP53):c.730G>T (p.Gly244Cys) SNV Likely Pathogenic
376599 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
17 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely Pathogenic
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
18 TP53 NM_000546.6(TP53):c.796G>C (p.Gly266Arg) SNV Likely Pathogenic
376605 rs1057519990 GRCh37: 17:7577142-7577142
GRCh38: 17:7673824-7673824
19 TP53 NM_000546.6(TP53):c.712T>C (p.Cys238Arg) SNV Likely Pathogenic
376576 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
20 TP53 NM_000546.6(TP53):c.374C>G (p.Thr125Arg) SNV Likely Pathogenic
376667 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
21 TP53 NM_000546.6(TP53):c.658T>C (p.Tyr220His) SNV Likely Pathogenic
376687 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
22 TP53 NM_000546.6(TP53):c.637C>G (p.Arg213Gly) SNV Likely Pathogenic
376651 rs397516436 GRCh37: 17:7578212-7578212
GRCh38: 17:7674894-7674894
23 TP53 NM_000546.6(TP53):c.817C>A (p.Arg273Ser) SNV Likely Pathogenic
376656 rs121913343 GRCh37: 17:7577121-7577121
GRCh38: 17:7673803-7673803
24 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Likely Pathogenic
135359 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
25 TP53 NM_000546.6(TP53):c.824G>C (p.Cys275Ser) SNV Likely Pathogenic
376583 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
26 TP53 NM_000546.6(TP53):c.731G>A (p.Gly244Asp) SNV Likely Pathogenic
372785 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
27 TP53 NM_000546.6(TP53):c.845G>A (p.Arg282Gln) SNV Likely Pathogenic
237956 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
28 TP53 NM_000546.6(TP53):c.536A>T (p.His179Leu) SNV Likely Pathogenic
376608 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
29 TP53 NM_000546.6(TP53):c.797G>T (p.Gly266Val) SNV Likely Pathogenic
233303 rs193920774 GRCh37: 17:7577141-7577141
GRCh38: 17:7673823-7673823
30 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Likely Pathogenic
12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
31 TP53 NM_000546.6(TP53):c.842A>T (p.Asp281Val) SNV Likely Pathogenic
182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
32 TP53 NM_000546.6(TP53):c.583A>T (p.Ile195Phe) SNV Likely Pathogenic
376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
33 TP53 NM_000546.6(TP53):c.764T>A (p.Ile255Asn) SNV Likely Pathogenic
232289 rs876659675 GRCh37: 17:7577517-7577517
GRCh38: 17:7674199-7674199
34 TP53 NM_000546.6(TP53):c.733G>T (p.Gly245Cys) SNV Likely Pathogenic
12349 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
35 PTEN NM_000314.8(PTEN):c.698G>A (p.Arg233Gln) SNV Likely Pathogenic
376510 rs770025422 GRCh37: 10:89717673-89717673
GRCh38: 10:87957916-87957916
36 TP53 NM_000546.6(TP53):c.646G>T (p.Val216Leu) SNV Likely Pathogenic
376670 rs730882025 GRCh37: 17:7578203-7578203
GRCh38: 17:7674885-7674885
37 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely Pathogenic
95047 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617
38 TP53 NM_000546.6(TP53):c.841G>A (p.Asp281Asn) SNV Likely Pathogenic
376586 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
39 TP53 NM_000546.6(TP53):c.536A>C (p.His179Pro) SNV Likely Pathogenic
376611 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
40 TP53 NM_000546.6(TP53):c.734G>A (p.Gly245Asp) SNV Likely Pathogenic
12355 rs121912656 GRCh37: 17:7577547-7577547
GRCh38: 17:7674229-7674229
41 TP53 NM_000546.6(TP53):c.745A>G (p.Arg249Gly) SNV Likely Pathogenic
376654 rs587782082 GRCh37: 17:7577536-7577536
GRCh38: 17:7674218-7674218
42 TP53 NM_000546.6(TP53):c.537T>G (p.His179Gln) SNV Likely Pathogenic
376607 rs876660821 GRCh37: 17:7578393-7578393
GRCh38: 17:7675075-7675075
43 TP53 NM_000546.6(TP53):c.746G>A (p.Arg249Lys) SNV Likely Pathogenic
142241 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
44 BRAF NM_004333.6(BRAF):c.1787G>T (p.Gly596Val) SNV Likely Pathogenic
40387 rs397507483 GRCh37: 7:140453148-140453148
GRCh38: 7:140753348-140753348
45 TP53 NM_000546.6(TP53):c.581T>A (p.Leu194His) SNV Likely Pathogenic
376634 rs1057519998 GRCh37: 17:7578268-7578268
GRCh38: 17:7674950-7674950
46 TP53 NM_000546.6(TP53):c.700T>G (p.Tyr234Asp) SNV Likely Pathogenic
219759 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
47 TP53 NM_000546.6(TP53):c.613T>A (p.Tyr205Asn) SNV Likely Pathogenic
376684 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
48 TP53 NM_000546.6(TP53):c.584T>C (p.Ile195Thr) SNV Likely Pathogenic
216077 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
49 TP53 NM_000546.6(TP53):c.535C>A (p.His179Asn) SNV Likely Pathogenic
376609 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
50 TP53 NM_000546.6(TP53):c.722C>T (p.Ser241Phe) SNV Likely Pathogenic
12359 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241

Copy number variations for Glioblastoma from CNVD:

6 (show top 50) (show all 797)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13758 1 1 28000000 Copy number Glioblastoma
10 13761 1 1 28000000 Deletion Glioblastoma multiforme
11 13763 1 1 28000000 Gain Glioblastoma multiforme
12 13775 1 1 39600000 Loss Glioblastoma multiforme
13 13792 1 1 51300000 Loss Glioblastoma multiforme
14 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
15 14314 1 107000000 111600000 Gain Glioblastoma multiforme
16 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
17 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
18 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
19 16435 1 124300000 247249719 Gain Glioblastoma multiforme
20 16436 1 124300000 247249719 Gain Glioblastoma multiforme
21 16437 1 124300000 247249719 Gain Glioblastoma multiforme
22 16444 1 124300000 247249719 Loss Glioblastoma multiforme
23 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
24 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
25 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
26 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
27 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
28 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
29 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
30 23682 1 172900000 185800000 Gain Glioblastoma multiforme
31 24288 1 178190530 178346919 Fusion CEP350 Glioblastoma multiforme
32 25428 1 189000000 197500000 Gain Glioblastoma multiforme
33 25567 1 191357783 191486465 Fusion CDC73 Glioblastoma multiforme
34 26137 1 197500000 205300000 Amplification LRRN2 Glioblastoma multiforme
35 26138 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
36 26139 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
37 26142 1 197500000 205300000 Amplification NFASC Glioblastoma multiforme
38 26146 1 197500000 205300000 Amplificationlication MDM2 Glioblastoma multiforme
39 26474 1 200429740 200554958 Truncation LGR6 Glioblastoma multiforme
40 26515 1 200858000 202110000 Copy number MDM4 Glioblastoma multiforme
41 26660 1 201942811 203355851 Amplification MDM4 Glioblastoma multiforme
42 28554 1 223214607 229308654 Gain ARF1 Glioblastoma multiforme
43 28555 1 223214607 229308654 Gain WNT3A Glioblastoma multiforme
44 29626 1 233890968 234060340 Fusion LYST Glioblastoma multiforme
45 30289 1 241700000 247249719 Amplification AKT3 Glioblastoma multiforme
46 30312 1 241718157 242073207 Amplification AKT3 Glioblastoma
47 30407 1 2429834 2447886 Fusion PANK4 Glioblastoma multiforme
48 31747 1 30500000 171200000 Gain Glioblastoma multiforme
49 32775 1 3928417 3978407 Deletion Glioblastoma multiforme
50 32899 1 4028404 6333694 Deletion AJAP1 Glioblastoma multiforme

Expression for Glioblastoma

Search GEO for disease gene expression data for Glioblastoma.

Pathways for Glioblastoma



Pathways directly related to Glioblastoma:

# Pathway Source
1 Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate Reactome 66

Pathways related to Glioblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.63 MIR222 MIR221 MIR21

GO Terms for Glioblastoma

Cellular components related to Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.8 MIR326 MIR296 MIR222 MIR221 MIR21 MIR17HG
2 extracellular vesicle GO:1903561 9.02 MIR451A MIR34A MIR222 MIR221 MIR21

Biological processes related to Glioblastoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell migration GO:0030336 9.87 MIR451A MIR34A MIR21 MIR137
2 negative regulation of angiogenesis GO:0016525 9.78 MIR34A MIR222 MIR21 MIR137
3 negative regulation of protein kinase B signaling GO:0051898 9.73 MIR451A MIR34A MIR137
4 positive regulation of epithelial to mesenchymal transition GO:0010718 9.72 MIR222 MIR221 MIR21
5 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.7 MIR222 MIR221 MIR21
6 negative regulation of vascular associated smooth muscle cell proliferation GO:1904706 9.69 MIR34A MIR182 MIR137
7 positive regulation of axon regeneration GO:0048680 9.59 MIR222 MIR221
8 negative regulation of cell adhesion molecule production GO:0060354 9.58 MIR222 MIR221
9 negative regulation by host of viral genome replication GO:0044828 9.58 MIR222 MIR221
10 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.56 MIR222 MIR221 MIR21 MIR182
11 miRNA-mediated gene silencing GO:0035195 9.55 MIR451A MIR34A MIR326 MIR296 MIR222 MIR221
12 negative regulation of xenobiotic detoxification by transmembrane export across the plasma membrane GO:1905700 9.54 MIR451A MIR326
13 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.54 MIR451A MIR221 MIR21
14 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.49 MIR222 MIR221
15 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.46 MIR222 MIR221
16 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.46 MIR34A MIR21 MIR182 MIR137
17 positive regulation of Schwann cell migration GO:1900149 9.43 MIR221 MIR222
18 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.4 MIR221 MIR222
19 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.32 MIR222 MIR221
20 negative regulation of interleukin-21 production GO:0032705 9.13 MIR222 MIR221 MIR21

Molecular functions related to Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.43 MIR451A MIR34A MIR326 MIR296 MIR21 MIR137
2 mRNA base-pairing translational repressor activity GO:1903231 9.28 MIR451A MIR34A MIR326 MIR296 MIR222 MIR221

Sources for Glioblastoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....